Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Downgraded by Wall Street Zen to "Buy"

Key Points

• Wall Street Zen downgraded Fresenius Medical Care from "strong-buy" to "buy," and several other firms including Weiss, Goldman Sachs and Jefferies have recently cut their ratings, signaling weakening sell-side sentiment.
• The stock has a consensus analyst rating of "Reduce" with an average price target of $28, comprised of five Hold and four Sell ratings.
• FMS trades near $22.45 (1‑year range $20.94–$30.46) with a $12.54 billion market cap and a P/E of 11.75; the company reported $1.69 EPS and $5.95 billion in revenue for the most recent quarter.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "strong-buy" rating to a "buy" rating in a research note issued on Saturday.

Several other analysts have also recently commented on FMS. Weiss Ratings cut shares of Fresenius Medical Care AG & Co. KGaA from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Friday, March 13th. The Goldman Sachs Group lowered shares of Fresenius Medical Care AG & Co. KGaA from a "buy" rating to a "neutral" rating in a research report on Tuesday, January 20th. Jefferies Financial Group cut shares of Fresenius Medical Care AG & Co. KGaA from a "moderate sell" rating to a "strong sell" rating in a report on Tuesday, February 24th. Morgan Stanley reiterated an "underweight" rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, January 27th. Finally, Truist Financial set a $28.00 price target on Fresenius Medical Care AG & Co. KGaA in a research note on Monday, January 5th. Five equities research analysts have rated the stock with a Hold rating and four have given a Sell rating to the company. According to data from MarketBeat, Fresenius Medical Care AG & Co. KGaA has a consensus rating of "Reduce" and an average target price of $28.00.

Fresenius Medical Care AG & Co. KGaA Trading Up 0.2%

NYSE:FMS opened at $22.45 on Friday. Fresenius Medical Care AG & Co. KGaA has a 1 year low of $20.94 and a 1 year high of $30.46. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.92 and a current ratio of 1.26. The stock has a fifty day moving average price of $23.09 and a two-hundred day moving average price of $24.03. The stock has a market capitalization of $12.54 billion, a price-to-earnings ratio of 11.75, a PEG ratio of 2.12 and a beta of 0.89.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report) last issued its earnings results on Saturday, February 14th. The company reported $1.69 EPS for the quarter. Fresenius Medical Care AG & Co. KGaA had a net margin of 5.03% and a return on equity of 8.73%. The company had revenue of $5.95 billion for the quarter. As a group, sell-side analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 1.51 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Fresenius Medical Care AG & Co. KGaA

A number of large investors have recently added to or reduced their stakes in the business. Morgan Stanley increased its holdings in Fresenius Medical Care AG & Co. KGaA by 47.2% during the 4th quarter. Morgan Stanley now owns 2,939,839 shares of the company's stock valued at $70,027,000 after acquiring an additional 942,497 shares in the last quarter. Bank of America Corp DE lifted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 279.7% in the second quarter. Bank of America Corp DE now owns 337,316 shares of the company's stock valued at $9,637,000 after purchasing an additional 248,477 shares in the last quarter. ABC Arbitrage SA lifted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 1,136.0% in the fourth quarter. ABC Arbitrage SA now owns 249,800 shares of the company's stock valued at $5,950,000 after purchasing an additional 229,589 shares in the last quarter. Integral Health Asset Management LLC grew its position in shares of Fresenius Medical Care AG & Co. KGaA by 44.4% in the fourth quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company's stock valued at $15,483,000 after purchasing an additional 200,000 shares during the last quarter. Finally, Pzena Investment Management LLC grew its position in shares of Fresenius Medical Care AG & Co. KGaA by 1.0% in the third quarter. Pzena Investment Management LLC now owns 14,816,852 shares of the company's stock valued at $390,128,000 after purchasing an additional 153,870 shares during the last quarter. 8.37% of the stock is owned by institutional investors and hedge funds.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world's largest integrated provider of products and services for individuals with renal diseases. The company's primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.